Silence Therapeutics plc (SLN) stock
SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
$19.80−0.03 (-0.15%)
Close on Nov 16, 2026Market cap $935.48MP/E –Yield –
Silence Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Silence Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $36.32M, down 55.2% year over year. For fiscal 2025 it was $67.75M, down 0.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.75M | -0.2% |
| FY2024 | Dec 31, 2024 | $67.88M | +19.2% |
| FY2023 | Dec 31, 2023 | $56.94M | +30.7% |
| FY2022 | Dec 31, 2022 | $43.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.30M | -54.7% |
| Q2 FY2026 | Jun 30, 2026 | $9.15M | -48.2% |
| Q1 FY2026 | Mar 31, 2026 | $9.12M | -56.2% |
| Q4 FY2025 | Dec 31, 2025 | $8.75M | -60.4% |
| Q3 FY2025 | Sep 30, 2025 | $20.54M | +1.9% |
| Q2 FY2025 | Jun 30, 2025 | $17.65M | +27.9% |
| Q1 FY2025 | Mar 31, 2025 | $20.81M | +75.7% |
| Q4 FY2024 | Dec 31, 2024 | $22.08M | – |
| Q3 FY2024 | Sep 30, 2024 | $20.16M | – |
| Q2 FY2024 | Jun 30, 2024 | $13.80M | – |
| Q1 FY2024 | Mar 31, 2024 | $11.85M | – |
See a number that looks wrong?